Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
INCYTE CORP
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-26.1% vs price
Base Case (Median)
-1.3% vs price
Bull Case (75th pct.)
66.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $113.84 | -1.3% | High (40%) |
| PE Comparable | $176.27 | 52.9% | Medium (25%) |
| Growth Trajectory DCF | $370.94 | 221.7% | Medium (20%) |
| Graham Number | $67.49 | -41.5% | Medium (40%) |
| EV/EBITDA | $103.03 | -10.6% | Medium (20%) |
| EV/FCF | $206.87 | 79.4% | Medium (20%) |
| Earnings Power Value | $46.37 | -59.8% | Medium (50%) |
Based on 7 out of 7 methods, INCY appears fairly valued at the current price of $115.30. The base case fair value of $113.84 implies 1.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.